Humana Checkpoint Controls and Targets in Cancer Therapy (Cancer Drug Discovery and Development)

Checkpoint regulation is critical in understanding cancer development and cancer therapy. This book builds upon existing concepts of checkpoints and aims to expand our understanding of the inner workings of the critical checkpoint machinery. Review From the reviews: “This nicely organized book focuses on cell cycle checkpoint and cancer biology/therapeutics. … The book is written for graduate students, residents, and postdoctoral investigators in basic, translational, or clinical cancer research. The contributing authors are active investigators at the forefront of this field. … This book presents timely, comprehensive reviews of the rapidly progressing field of checkpoint. It should be quite useful for readers who are seeking a solid grasp of updated information in this field.” (Hiroaki Kiyokawa, Doody’s Review Service, March, 2010) From the Back Cover   There is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are closely associated with cancers that are highly resistant to therapeutic interventions. Checkpoint Controls and Targets in Cancer provides present-day mechanistic understandings of how multiple sets of proteins orchestrate cell cycle progression, discusses critical checkpoint controls that are evaded for cancer development, focuses on checkpoint pathways associated with antitumor effects, and identifies specific checkpoint regulators for targeting with small molecules in the clinical management of cancer. These aspects of cell cycle checkpoints are articulated critically by renowned experts from both academia and industry, and new concepts are forwarded that challenge existing dogmas. Collectively, Checkpoint Controls and Targets in Cancer provides a unique collection of insightful contributions, which are timely and offer significant interest and appeal to basic, translational and clinical scientists.